Member Info for busicat

75p paid today is highest in 3 years going by HL, showing w/com2/8/21 was last time this level was reached (allowing for the share aggregation. Feeling more hopeful this one moving towards the recognition it desrves.

Price rocketing in July seems to be a regular occurrence with this one. Happy to see it keep going!

Impatience seems to have created a bargain price here

Nicely on track

Got my little top up at 3.325 and happy to sit back and watch the fun

Start of reversal looks possible for today, so I've topped up accordingly...which probably means simply a repeat of Thursday morning's promising start, only to continue to drift down. But as there's less than a month to 24 July update Sisyphus mentions, I'm optimistic a turn up is on the way, if only in anticipation.

Perhaps engineerinvests forgets UK NHS was ranked most efficient out of 7 comparable developed nations in 2010, and top out of 11 in 2014 thanks to the sound foundations established over the many years before, sliding since then, as was predicted by the BMA, due to Tory refusal to match spending to need .

16th place in Europe is a Tory benefit.

NHS good news for greenlight on the new TrueVue System

Maybe not as bad as expected?

Nice surprise of just 0.0362 to buy. Never thought I'd get a chance to buy this one so near to a placing price when so confident of progress.

Returning to the protection sales opportunity when new mortgage sales are low which we speculated on in October, I note that today Andy Walton of MAB1 is reported as saying

"“As a business, we became more focused on protection conversations at the mortgage product end date." and

“Subsequently, we saw a 21% increase in protection sales in 2023.”

https://healthcareandprotection.com/why-truss-mini-budget-focussed-renters-minds-on-the-need-for-income-protection-analysis/

Move to profitability looking closer?

Interesting sudden jump back up almost to pre Nov drop level

No idea - also why moves so fast on so little

Hmm - could go either way. Although revenue + costs going in right direction, "Downside scenario" could mean cash exhausted in 12 months.

"We have a clear strategy to ensure sufficient cash resources to get us to profitability, however as a high growth MedTech company future revenues and future investment are not committed and this represents a material uncertainty resulting in significant doubt in respect of going concern as disclosed in the 2023 annual report and accounts. However, we believe that the current revenue trajectory, future licensing deals and operating cost flexibility provide a clear strategy to ensure sufficient cash resources to get us to profitability."

"The Directors have prepared a base case scenario which is based on the Board approved forecast and assumes an increase in revenues particularly from its core revenue streams and Kamaptive licensing programme for the year to 31 December 2024 compared to the year ended 31 December 2023. In addition, the Directors have modelled a severe but plausible downside scenario for the going concern period. This scenario includes sensitivity analysis to delay a proportion of future expected but not contracted growth in revenue and assumes no savings in expenditure are made. This downside scenario indicated that the cash resources of the Group would be exhausted in around 12 months from the date of approval of the financial statements, and a breach of loan covenants will occur within 12 months, before taking account of mitigating actions. The Directors have identified several areas where a reduction in expenditure on the Group's research and development programme and other areas could be made if such a scenario were to occur to ensure the Group would be able to meet its liabilities as they fall due for the going concern period, without needing to obtain waivers on the debt covenants."

"The Group continues to make progress towards profitability as we continue to seek to ramp up commercialisation. The Directors have identified several potential sources of funding which could provide sufficient cash to the business to reach positive cash generation, should a downside scenario arise. At present these sources of funding remain uncommitted and a substantial proportion of the forecast revenues remains uncommitted for the going concern period and beyond. The Directors recognise that if no additional funding is secured during the next 12 months or if the Group fails to secure additional revenue contracts as forecast then the Group may breach debt covenants and may not have sufficient resources to meet its liquidity requirements and be unable to continue as a going concern. "

Final results should confirm cash runway on Wednesday I hope!

"All of the Company's Directors intend to participate in the Fundraising either via the Placing, the REX Offer or the Open Offer. The £ sterling amount they each intend to subscribe for is as follows: James Cheek - £10,000, Russ Shaw - £25,500, Gino Miele - £9,000, Ian Gilham £10,000, Tom Lindsay - £10,000 and Chris Yates - £3,000."

Up 10% in a week feels better. Hoping not to see under 700 again now.

Unusual. A flicker of life?

Stock saint - you can generally re-enter and continue the lse chat for closed stocks via Google, eg C4XD Share Chat